Seattle Treatment Education Project
STEP Perspective
Table of Contents, Spring 2003
- A STEP Conference Review: 10th Conference on Retroviruses and Opportunistic Infections
By Lara Strick, M.D. and Jeffrey T. Schouten, M.D.
- The 2NN Study
By Lara Strick, M.D.
- Dear Healthcare Provider Letter From the Division of AIDS -- Concern About Trizivir Potency
By Jeffrey T. Schouten, M.D.
- AIDS-Related Cancers: An Update
By Jeffrey T. Schouten, M.D.
- Lipodystrophy and Metabolic Complications of HIV and Antiretroviral Therapies
By Benjamin Young, M.D., Ph.D.
- The VaxGen Study
By Dennis Torres
- Fuzeon (T-20), the First HIV Entry Inhibitor, Is Now FDA-Approved
By Jeffrey T. Schouten, M.D.
- HIV Studies at Swedish Research Center
- University of Washington ACTU Seeks Participants for Two New Studies
- Ask Dr. Jeff
By Jeffrey T. Schouten, M.D.
This article was provided by
Seattle Treatment Education Project.
It is a part of the publication STEP Perspective.
